Abstract
Prosthetic valve endocarditis (PVE) caused by Pseudomonas aeruginosa is a rare but life-threatening complication. Early surgical intervention, as well as appropriate antimicrobial therapy, is usually necessary. Recently, problems have arisen regarding infection with P. aeruginosa, which produces metallo-beta-lactamase (MBL) and is resistant to virtually all beta-lactams. This organism has rapidly spread through many countries. Here, we report the first case of successful redo aortic valve replacement using a Prima Plus stentless valve (Edwards Lifesciences, Irvine, CA, USA) followed by a 6-week course of ciprofloxacin and gentamicin for early PVE caused by MBL-producing P. aeruginosa.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
